Evidence map›Paper›PMID 39524920›Full record

ReviewInternational journal of nanomedicine2024

Metal-Phenolic Networks: A Promising Frontier in Cancer Theranostics.

Lingjun Li, Jiaoyang Pan, Mengwei Huang, Jiamin Sun, Cheng Wang, Hongbin Xu

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Multifunctional CuFrontiers in chemistry · 2026
    Review
  8. Review
  9. Review
  10. Metal-Ligand Complexes as Multifunctional Platforms for Photo-Activated Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lingjun LiDepartment of Reproductive Medicine Center, Changzhou Maternal and Child Health Care Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu Province, People's Republic of China.
Jiaoyang PanSchool of Pharmacy, Changzhou University, Changzhou, Jiangsu Province, People's Republic of China.
Mengwei HuangObstetrics and Gynecology Department, The Third Affiliated Hospital of Nanjing Medical University (Changzhou No. 2 People's Hospital), Changzhou, Jiangsu Province, People's Republic of China.
Jiamin SunObstetrics and Gynecology Department, The Third Affiliated Hospital of Nanjing Medical University (Changzhou No. 2 People's Hospital), Changzhou, Jiangsu Province, People's Republic of China.
Cheng WangSchool of Pharmacy, Changzhou University, Changzhou, Jiangsu Province, People's Republic of China.ORCID 0000-0003-3873-7350
Hongbin XuObstetrics and Gynecology Department, The Third Affiliated Hospital of Nanjing Medical University (Changzhou No. 2 People's Hospital), Changzhou, Jiangsu Province, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The burgeoning field of cancer theranostics has been significantly advanced by the development of Metal-Phenolic Networks (MPNs), a new class of supramolecular architectures that integrate the advantages of metals and polyphenols. This review focuses on MPNs and their promising applications in cancer theranostics. Through a systematic literature search spanning from 2010 to 2023 in databases including PubMed, Scopus, and Web of Science. The period of search was justified by the rapid evolution of nanomaterials in cancer therapy, with MPNs emerging as a significant player in biomedical applications within the specified timeframe. This review discusses the classification and structure of polyphenolic compounds, as well as their mechanisms of action in cancer treatment. The applications of MPNs in chemotherapy drug delivery, photothermal therapy, chemodynamic therapy, biomedical imaging, and synergistic therapy are especially detailed. The authors emphasize the significance of MPNs in cancer nanomedicine and look forward to their future development directions.

Indexed as

MetalsNeoplasmsTheranostic NanomedicineAnimalsAntineoplastic AgentsDrug Delivery SystemsHumansPhenolsPolyphenolsAntineoplastic AgentsMetalsPhenolsPolyphenolscancerMPNpolyphenolic compoundstheranostics

Identifiers

PMID39524920
PMCPMC11550784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.